ImClone Investigational Site

Los Angeles, California 90095

0 studies enrolling now · 12 studies all time

What they study most

Breast Cancer, Carcinoma, Colorectal Cancer, Colorectal Neoplasms, Gastric Cancer, Hepatocellular Carcinoma, Metastases, Neoplasm, Neuroendocrine Tumors, Non-small Cell Lung Cancer, Sarcoma, Soft Tissue

Studies at this site

• Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer — Completed
• A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer — Completed
• A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma — Completed
• Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients — Completed
• Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy — Completed
• A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver — Completed
• A Study of Olaratumab in Soft Tissue Sarcoma — Completed
• Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy — Completed
• Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer — Completed